You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,855,223


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,855,223
Title:Method of treating inflammatory arthritis
Abstract: The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-.alpha. or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.
Inventor(s): Chen; Ruihuan (Palo Alto, CA), Mencher; Simon K. (New York, NY), Tsao; Allen (Windlake, WI), Liu; Xiao Mei (Flushing, NY), Wang; Longgui (Flushing, NY)
Assignee: Natrogen Therapeutics International, Inc. (New York, NY)
Application Number:11/494,362
Patent Claims:1. A method of treating rheumatoid arthritis comprising administering to an animal suffering from rheumatoid arthritis a therapeutically effective amount of at least one compound selected from the group consisting of: formulas (IV), (V), and (VI) respectively: ##STR00004## wherein the amount is sufficient to treat the rheumatoid arthritis by inhibiting pro-inflammatory cytokine expression and/or by stimulating anti-inflammatory cytokines, but less than sufficient to substantially inhibit cyclin dependent kinases (CDKs).

2. The method of claim 1, wherein the compound is the compound of formula (IV): ##STR00005##

3. The method of claim 1, wherein the compound is administered during the induction phase of the rheumatoid arthritis.

4. The method of claim 3, wherein the animal is a human and the compound is administered orally, mucosally, parenterally, topically, or transdermally.

5. The method according to claim 4, wherein administration of the compound is in an amount of 5 to 100 mg/day.

6. The method of claim 1, wherein the animal is diagnosed with rheumatoid arthritis and the compound is administered in conjunction with an agent selected from the group consisting of: an analgesic, a COX-2 inhibitor, a corticosteroid, non-steroidal anti-inflammatory drug (NSAID); a disease modifying anti-rheumatic drug (DMARD); and a biologic disease modifying anti-rheumatic drug (biologic DMARD).

7. The method of claim 6, wherein the agent is an analgesic selected from the group consisting of: acetaminophen, aspirin, codeine, propoxyphene, fentanyl, hydromorphone, morphine, morphine sulfate, oxycodone, pentazocine, tramadol, hydrocodone, naproxen, indomethacin, ibuprofen, fenoprofen, ketorolac tromethamine, choline magnesium trisalicylate, and combinations thereof.

8. The method of claim 6, wherein the agent is selected from the group consisting of: rofecoxib, valdecoxib, parecoxib, etoricoxib, celecoxib, betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, salicylate, arylalkanoic acid, 2-arylpropionic acid, N-arylanthranilic acid, oxiam, coxib, sulphonanilide, hydroxychloroquine, chloroquine, leflunomide, methotrexate, sulfasalazine, gold, gold thiomalate, aurothioglucose, auranofin, azathioprine, cyclophosphamide, anti-tumor necrosis factor (anti-TNF), etanercept, infliximab, and adalimumab, anti-IL-1, anti-CD20, anakinra, or combinations thereof.

9. The method of claim 1, wherein administration of the compound is in an oral formulation and is administered for a period of at least 45 days.

10. The method according to claim 1, wherein at least two compounds are administered concurrently or sequentially in an extended release formulation.

11. The method according to claim 1, wherein the compound is administered in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

12. The method according to claim 1, wherein the compound is administered at a concentration sufficient to inhibit at least one cytokine selected from the group consisting of IL-1.alpha., .beta., IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-.alpha., LT, LIF, Oncostatin, or IFNc1.alpha., .beta., .gamma.; and/or stimulate expression of at least one cytokine selected from the group consisting of IL-4, IL-10, IL-11, W-13 or TGF.beta..

13. The method of claim 1, wherein the compound is administered in an amount sufficient to modulate cytokines TNF-.alpha., IL-1.beta., IL-6, and IL-10.

Details for Patent 7,855,223

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2024-01-12
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2024-01-12
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2024-01-12
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2024-01-12
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2024-01-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.